Cite
Lipidomics Reveals Reduced Inflammatory Lipid Species and Storage Lipids after Switching from EFV/FTC/TDF to RPV/FTC/TDF: A Randomized Open-Label Trial.
MLA
Curran, Adrian, et al. “Lipidomics Reveals Reduced Inflammatory Lipid Species and Storage Lipids after Switching from EFV/FTC/TDF to RPV/FTC/TDF: A Randomized Open-Label Trial.” Journal of Clinical Medicine, vol. 9, no. 5, May 2020, p. 1246. EBSCOhost, https://doi.org/10.3390/jcm9051246.
APA
Curran, A., Rull, A., Navarro, J., Vidal-González, J., Martin-Castillo, M., Burgos, J., Falcó, V., Ribera, E., Torrella, A., Planas, B., Peraire, J., & Crespo, M. (2020). Lipidomics Reveals Reduced Inflammatory Lipid Species and Storage Lipids after Switching from EFV/FTC/TDF to RPV/FTC/TDF: A Randomized Open-Label Trial. Journal of Clinical Medicine, 9(5), 1246. https://doi.org/10.3390/jcm9051246
Chicago
Curran, Adrian, Anna Rull, Jordi Navarro, Judit Vidal-González, Mario Martin-Castillo, Joaquin Burgos, Vicenç Falcó, et al. 2020. “Lipidomics Reveals Reduced Inflammatory Lipid Species and Storage Lipids after Switching from EFV/FTC/TDF to RPV/FTC/TDF: A Randomized Open-Label Trial.” Journal of Clinical Medicine 9 (5): 1246. doi:10.3390/jcm9051246.